Day: February 4, 2026

Geneva, Switzerland, Feb. 04, 2026 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology ardware and software products, today announced that its CEO, Carlos Moreira, during his keynote at Tech&Fest (Progress Stage), presented the strategic vision and technical progress of a vertically integrated sovereign root-to-quantum security platform currently under development. Addressing the accelerating risks posed by quantum computing to embedded and mission-critical systems, Mr. Moreira emphasized the urgency of preparing for Q-Day, the moment when quantum capabilities render today’s cryptography obsolete. He outlined Europe’s need to act decisively to secure its digital, industrial, defense,...

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February: Guggenheim Securities Emerging Outlook: Biotech SummitDate: February 11, 2026Time: 10:30 a.m. ETFormat: Fireside ChatLocation: New York, NY Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: February 25, 2026Time: 8:40 a.m. ETFormat: Fireside Chat Location: Virtual To access a live webcast of these events, as well as an archived recording, please visit the Investors & Media section of the Company’s website at www.sab.bio.   About SAB BIOSAB BIO is a clinical-stage...

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company’s 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a grant date of January 26, 2026, and an exercise price of $1.46 per share, which is equal to the closing price of Autolus’...

TEL AVIV, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) — HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”), a global leader in confidential computing and secured data fabric technologies, today announced an open letter by its CEO, Noah Hershcoviz, to its shareholders. Dear Shareholders, HUB operates in environments where trust failure is not an option. The Company’s foundation is built on military-grade cybersecurity and Secured Data Fabric (“SDF”) infrastructure designed to secure, govern, and operationalize sensitive data across regulated, sovereign, and adversarial environments. That foundation continues to strengthen through HUB’s deployments, ongoing institutional adoption, and growing operational scale. We are witnessing sustained demand by the market and expect to see continued growth during 2026 across our revenue...

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with interim data expected by the end of 2026 Pelareorep now has Fast Track Designation for two gastrointestinal cancers, solidifying its potential as an immunotherapeutic platform therapy in gastrointestinal cancers SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to pelareorep in combination with bevacizumab (Avastin®) and leucovorin, fluorouracil, irinotecan (“FOLFIRI”) for the treatment of patients...

MIAMI BEACH, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) — Cuentas, Inc. (OTCID: CUEN & CUENW) (“Cuentas”) Cuentas, Inc. (the “Company”) today announced that it had extended the expiration date of its publicly traded warrants (OTCID: CUENW) (the “Warrants”) from February 4, 2026 to June 30, 2026. The Warrants were issued and sold by the Company on February 4, 2021 as part of a firm commitment public offering of its units, consisting of one share of its common stock, par value $0.001 per share (“Common Stock”), and a warrant to purchase an additional share of Common Stock exercisable for five years at an exercise price of $4.30 per share (the “Warrants”). The Company sold an aggregate of 2,790,697 units at a price to the public of $4.30 per unit in the offering. The Common Stock and the Warrants were offered and sold to the public...

PHOENIX, Feb. 04, 2026 (GLOBE NEWSWIRE) — Fold Holdings, Inc. (NASDAQ: FLD) (“Fold” or the “Company”), a bitcoin financial services company making it easy for individuals to earn, save and spend bitcoin through everyday financial tools, today announced the launch of a new Fold app experience that brings rewards, spending, and account activity together into a single, intuitive financial hub, giving customers a clearer, more convenient view of their money. Over the past year, Fold has paid close attention to how customers use money and bitcoin. The updated app experience reflects that feedback by bringing balances, transactions, bitcoin rewards, and spending activity into a single, easy-to-navigate hub. By simplifying how customers earn, track, and use bitcoin in one place, Fold helps them get more value from each action today while...